{"id":"NCT00179647","sponsor":"Celgene Corporation","briefTitle":"Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma","officialTitle":"A Multicenter, Single-Arm, Open-Label, Expanded Access Program for Lenalidomide With or Without Dexamethasone in Previously Treated Subjects With Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2008-12","completion":"2009-04","firstPosted":"2005-09-16","resultsPosted":"2010-03-03","lastUpdate":"2010-03-16"},"enrollment":1913,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"lenalidomide","otherNames":["Revlimid"]},{"type":"DRUG","name":"dexamethasone","otherNames":["Decadron"]}],"arms":[{"label":"Lenalidomide 5-25 mg, w/wo dexamethasone","type":"OTHER"}],"summary":"Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.","primaryOutcome":{"measure":"Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.","timeFrame":"Median time-on-study=18.3 weeks","effectByArm":[],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":69,"countries":["United States","Canada"]},"refs":{"pmids":["19332768"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":878,"n":1913},"commonTop":["FATIGUE","NEUTROPENIA","MUSCLE CRAMP","CONSTIPATION","DIARRHOEA"]}}